Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency
2017 · Molecular Neurodegeneration · 57 citations
https://doi.org/10.1186/s13024-017-0172-1
K
Konstantin Kazarian
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
14
Papers
534
Citations
8
h-index
8
i10-index
Konstantin Kazarian is an academic researcher from Oxford BioMedica (United Kingdom). The author has contributed to research in topics: Alzheimer's disease research and treatments & Neuroinflammation and Neurodegeneration Mechanisms & Computational Drug Discovery Methods. The author has an h-index of 8, co-authored 12 publications.
Papers by this author
worksAlzheimer’s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules
2016 · Scientific Reports · 46 citations
https://doi.org/10.1038/srep28912
Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials
2020 · Neurobiology of Disease · 39 citations
https://doi.org/10.1016/j.nbd.2020.104823
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat